Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMBNASDAQ:AVRNASDAQ:GALTOTCMKTS:RYMDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$18.43+1.6%$14.99$7.75▼$19.93$140.81M0.6227,579 shs20,099 shsAVRAnteris Technologies Global$3.54-6.8%$4.29$2.34▼$8.79$127.65MN/A219,556 shs197,555 shsGALTGalectin Therapeutics$2.11-3.2%$1.64$0.73▼$3.90$134.49M0.7412,161 shs314,945 shsRYMDFRelay Medical$0.01$0.01$0.13▼$0.72$2.07M1.1568,743 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences0.00%+4.85%+11.76%+110.31%+37.40%AVRAnteris Technologies Global0.00%-6.40%-19.83%+31.03%+379,999,900.00%GALTGalectin Therapeutics0.00%-7.51%+63.26%+62.64%+4.61%RYMDFRelay Medical0.00%0.00%-27.46%-55.42%-57.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASMBAssembly Biosciences3.666 of 5 stars3.33.00.04.71.80.00.0AVRAnteris Technologies GlobalN/AN/AN/AN/AN/AN/AN/AN/AGALTGalectin Therapeutics1.6427 of 5 stars3.50.00.00.02.81.70.0RYMDFRelay MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.67Moderate Buy$33.0079.06% UpsideAVRAnteris Technologies Global 3.00Buy$16.50366.10% UpsideGALTGalectin Therapeutics 3.00Buy$6.00184.36% UpsideRYMDFRelay Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RYMDF, ASMB, GALT, and AVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$28.52M4.94N/AN/A$5.25 per share3.51AVRAnteris Technologies Global$2.70M47.28N/AN/A$1.74 per share2.03GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ARYMDFRelay MedicalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)AVRAnteris Technologies Global-$76.29MN/A0.00N/AN/AN/AN/AN/AN/AGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)RYMDFRelay MedicalN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest RYMDF, ASMB, GALT, and AVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/13/2025Q1 2025AVRAnteris Technologies GlobalN/A-$0.61N/A-$0.61N/AN/A5/8/2025Q1 2025ASMBAssembly Biosciences-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/AAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ARYMDFRelay MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A2.052.05AVRAnteris Technologies GlobalN/A3.673.65GALTGalectin TherapeuticsN/A0.080.08RYMDFRelay MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%AVRAnteris Technologies GlobalN/AGALTGalectin Therapeutics11.68%RYMDFRelay MedicalN/AInsider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.10%AVRAnteris Technologies GlobalN/AGALTGalectin Therapeutics50.10%RYMDFRelay MedicalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.64 million7.25 millionOptionableAVRAnteris Technologies Global13836.06 millionN/AN/AGALTGalectin Therapeutics963.29 million31.58 millionOptionableRYMDFRelay MedicalN/A241.20 millionN/ANot OptionableRYMDF, ASMB, GALT, and AVR HeadlinesRecent News About These CompaniesCNN’s Top Doc Relays Medical Community’s ‘Horror’ Over RFK Jr.November 15, 2024 | msn.comRelay For Life shares stories of cancer survival, awareness and aidOctober 9, 2024 | ridgecrestca.comRRelay Advancing Mutant PI3Kα Inhibitor into Phase III Breast Cancer TrialSeptember 9, 2024 | precisionmedicineonline.comPRelay Therapeutics' combo therapy for breast cancer cuts disease progression in early studySeptember 9, 2024 | reuters.comRelay Therapeutics Shares Jump on Positive Results for Breast Cancer TreatmentSeptember 9, 2024 | marketwatch.comRelay stock rallies 41% on positive data for RLY-2608September 9, 2024 | msn.comLafayette Cancer Care hosting annual Relay for LifeSeptember 6, 2024 | wlfi.comWRelay Kicks Off Its 2024 Fundraiser for St. Jude Children’s Research HospitalAugust 29, 2024 | macstories.netMJoin Relay and 9to5Mac in supporting St. Jude Children’s Research HospitalAugust 28, 2024 | 9to5mac.com9'Relay FM' Podcast Network Launches Annual Fundraiser for St. Jude Children's Research HospitalAugust 28, 2024 | macrumors.comMAmericans run blazing time in 4×100-meter relay — and could still get benched for Olympic finalsAugust 10, 2024 | nypost.comNFive talking points from the Paris Olympic Mixed Team RelayAugust 9, 2024 | triathlon.orgTYes, Kenny Bednarek can still run in the men's 4x100m relay finalAugust 9, 2024 | weareiowa.comWGermany wins dramatic gold medal after controversial mixed relay triathlon went ahead in River SeineAugust 5, 2024 | sports.yahoo.comSpringfield native Ryan Held and USA 4x100 freestyle relay team brings home the goldJuly 29, 2024 | wandtv.comWTeam USA wins first gold at 2024 Olympics in men’s 4×100-meter freestyle relayJuly 29, 2024 | nypost.comNMarket Outperform Rating Maintained for Relay Therapeutics Amidst Promising Developments of RLY-2608July 19, 2024 | markets.businessinsider.comRelay For Life ambassador sharing story of cancer fightMay 27, 2024 | altoonamirror.comABC Relay for Life goes onMay 19, 2024 | bc.eduBRXNT Announces Transition to Relay Exchange ClearinghouseMay 9, 2024 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRYMDF, ASMB, GALT, and AVR Company DescriptionsAssembly Biosciences NASDAQ:ASMB$18.43 +0.29 (+1.60%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Anteris Technologies Global NASDAQ:AVR$3.54 -0.26 (-6.84%) As of 02:40 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Galectin Therapeutics NASDAQ:GALT$2.11 -0.07 (-3.21%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Relay Medical OTCMKTS:RYMDF$0.0086 0.00 (0.00%) As of 07/3/2025Relay Medical Corp. operates as a medical technology company, which engages in the development of novel medical devices for in vitro diagnostics and point-of-care testing. Its platform technologies include HemoPalm and Pharmatrac. The HemoPalm develops a POCT unit-use cartridge based blood analyzer with full enterprise capabilities. The Pharmatrac is an AI and data analytics driven personal medication management system that addresses the growing problem of non-adherence to treatment. The company was founded by James Samsoondar in 2005 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
